

REFERENCES

- [1] Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. *CA-Cancer J Clin.* 2013; 63: 11–30.
- [2] Bilello K.S., Murin S., Matthay R.A. Epidemiology, etiology, and prevention of lung cancer. *Clin Chest Med.* 2002; 23: 1–25.
- [3] Visbal A.L., Leighl N.B., Feld R., Shepherd F.A. Adjuvant chemotherapy for early-stage non-small cell lung cancer. *Chest.* 2005; 128: 2933–2943.
- [4] Bertozzi C.R., Kiessling L.L. Chemical glycobiology. *Science.* 2001; 291: 2357–2364.
- [5] Fuster M.M., Esko J.D. The sweet and sour of cancer glycans as novel therapeutic targets. *Nature Rev.* 2005; 5: 526–542.
- [6] Ørntoft T.F., Vestergaard E.M. Clinical aspects of altered glycosylation of glycoproteins in cancer. *Electrophoresis.* 1999; 20: 362–371.
- [7] Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. *Nat Rev.* 2005; 4: 477–488.
- [8] Lau K.S., Dennis J.W. N-Glycan in cancer progression. *Glycobiology.* 2008; 18: 750–760.
- [9] Krueger K.E., Srivastava S. Posttranslational protein modification current implications for cancer detection, prevention, and therapeutics. *Mol Cell Proteomics.* 2006; 5: 1799–1810.
- [10] Durand G., Seta N. Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. *Clin Chem.* 2000; 46: 795–805.
- [11] Sriplung H., Sontipong S., Martin N. Cancer in Thailand 1995-1997. 2003; Vol. III. Bangkok: Bangkok Medical Publisher, 2003.
- [12] Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. *Nat Rev Cancer.* 2007; 7(10): 778–790.
- [13] Subramanian J., Govindan R. Lung cancer in never smokers: A Review. *J Clin Oncol.* 2007; 25: 567–570.

- [14] Alberg A.J., Brock M.V., Samet J.M. Epidemiology of lung cancer: Looking to the future. *J Clin Oncol.* 2005; 23: 3175–3185.
- [15] Galeone C., Negri E., Pelucchi C., Vecchia C.L., Bosetti C., Hu J. Dietary intake of fruit and vegetable and lung cancer risk: a case-control study in harbin, northeast china. *Ann Oncol.* 2007; 18: 388–392.
- [16] Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc.* 2008; 83: 584–594.
- [17] Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., Spitznagel E.L., Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiology and end results database. *J Clin Oncol.* 2006; 24: 4539–4544.
- [18] Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., Holmberg L., Yong L.C., Kolonel L.N., Gould M.K., West D.W. Lung cancer incidence in never smokers. *J Clin Oncol.* 2007; 25: 472–478.
- [19] Liu N.S., Spitz M.R., Kemp B.L., Cooksley C., Fossella F.V., Lee J.S., Hong W.K., Khuri F.R. Adenocarcinoma of the lung in young patients. *Cancer.* 2000; 88: 1837–1841.
- [20] Mulshine J.L. Current issues in lung cancer screening. *Oncology.* 2005; 19: 1724–1730; discussion 30–1.
- [21] Mountain C.F. Revisions in the international system for staging lung cancer. *Chest.* 1997; 111: 1710–1717.
- [22] Mason P. Lung cancer: the disease and non-drug treatment. *Hospital pharmacist.* 2005; 12: 129–135.
- [23] Mountain C.F. The international system for staging lung cancer. *Semin Sur Oncol.* 2000; 18: 106–115.
- [24] Lauren G.C., Haines C., Perkel R., Enck R.E. Lung cancer: Diagnosis and management. *Am Fam Physician.* 2007; 75: 56–63.
- [25] Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. *N Engl J.* 2004; 350: 379–392.

- [26] Fürst W., Schubert J., Machleidt W., Meyer H.E., Sandhoff K. The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator. *Eur J Biochem.* 1990; 192: 709–714.
- [27] Xie B., McInnes B., Neote K., Lamhonwah A.M., Mahuran D. Isolation and expression of a full-length cDNA encoding the human GM2 activator proteie. *Biochem Biophys Res Commun.* 1991; 177: 1217–1223.
- [28] Xie B., Rigat B., Georgijev N.S., Deng H., Mahuran D.J. Biochemical characterization of the Cys138Arg substitution associated with the AB variant form of GM2 gangliosidosis: evidence that Cys138 is required for the recognition of the GM2 activator/GM2 ganglioside complex by beta-hexosaminidase A. *Biochemistry.* 1998; 37: 814–821.
- [29] Glombitza G.J., Becker E., Kaiser H.W., Sandhoff K. Biosynthesis, processing, and intracellular transport of GM2 activator protein in human epidermal keratinocytes. *J Biol Chem.* 1997; 272: 5199–5207.
- [30] Sandhoff K., Kolter T., Harzer K. Sphingolipid activator proteins. In *The Metabolic and Molecular Bases of Inherited Disease*, ed. Scriver C.R., Beaudet A.L., Sly W.S., Valle, D. 2001; III: 3371–3388. New York: McGraw-Hill. 8th ed.
- [31] Wright C.S., Li S.C., Rastinejad F. Crystal structure of human GM2-activator protein with a novel beta-cup topology. *J Mol Biol.* 2000; 304: 411–422.
- [32] Rigat B., Wang W., Leung A., Mahuran D.J. Two mechanisms for the recapture of extracellular GM2 activator protein: evidence for a major secretory form of the protein. *Biochemistry.* 1997; 36: 8325–8331.
- [33] Hepbildikler S.T, Sandhoff R., Kölzer M., Proia R.L., Sandhoff K. Physiological substrates for human lysosomal β -hexosaminidase S. *J Biol Chem.* 2002; 277: 2562–2572
- [34] Conzelmann E., Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. *Proc Natl Acad Sci USA.* 1978; 75: 3979–3983.

- [35] Kolter T., Sandhoff K. Recent advances in the biochemistry of sphingolipidoses. *Brain Pathol.* 1998; 8: 79–100.
- [36] Birklé S., Zeng G., Gao L., Yu R.K., Aubry J. Role of tumor-associated gangliosides in cancer progression. *Biochimie.* 2003; 85: 455–463.
- [37] Kachman M.T., Wang H., Schwartz D.R., Cho K.R., Lubman DM. A 2-D liquid separations/mass mapping method for interlysate comparison of ovarian cancers. *Anal Chem.* 2002; 74: 1779–1791.
- [38] Wolters D.A., Washburn M.P., Yates J.R. An automated multidimensional protein identification technology for shotgun proteomics. *Anal Chem.* 2001; 73: 5683–5690.
- [39] Conrad D.H., Goyette J., Thomas P.S. Proteomics as a method for early detection of cancer: A review of proteomics, exhaled breath condensate, and lung cancer screening. *J Gen Intern Med.* 2007; 23: 78–84.
- [40] Garfin D.E. Two-dimensional gel electrophoresis: an overview. *Trends Anal. Chem.* 2003; 22: 263–272.
- [41] Fenn J.B., Mann M., Meng C.K., Wong S.F., Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. *Science.* 2003; 246: 64–71.
- [42] Melanson J.E., Chisholm K.A., Pinto D.M. Targeted comparative proteomics by liquid chromatography/matrix-assisted laser desorption/ionization triple-quadrupole mass spectrometry. *Rapid Commun. Mass Spectrom.* 2006; 20: 904–910.
- [43] Koomen J.M., Shih L.N., Coombes K.R., Li D., Xiao L.C., Fidler I.J., Abbruzzese J.L., Kobayashi, R. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. *Clin. Cancer. Res.* 2005; 11: 1110–1118.
- [44] Feuerstein I., Rainer M., Bernardo K., Stecher G., Huck C.W., Kofler K., Pelzer A., Horninger W., Klocker H., Bartsch G., Bonn G.K. Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling. *J. Proteome Res.* 2005; 4: 2320–2326.

- [45] Jensen O.N. Interpreting the protein language using proteomics. *Nature Rev Mol Cell Biol.* 2004; 5: 699–711.
- [46] Huang G., Zhang M., Erdman S.E. Posttranslational modifications required for cell surface localization and function of the fungal adhesion Aga1p. *Eukaryot Cell.* 2003; 2: 1099–1114.
- [47] Walsh C.T., Tsodikova G.S., Gatto G.J. Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem Int Ed.* 2005; 44: 7342–7372.
- [48] Dennis J.W., Granovsky M., Warren C.E. Glycoprotein glycosylation and cancer progression. *Biochim Biophys Acta.* 1999; 1473: 21–34.
- [49] Feizi T. Carbohydrate-mediated recognition systems in innate immunity. *Immunol Rev.* 2000; 173: 79–88.
- [50] Gorelik E., Galili U., Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. *Cancer Metastasis Rev.* 2001; 20: 245–277.
- [51] Wong C.H. Protein glycosylation: New challenges and opportunities. *J Org Chem.* 2005; 70: 4219–4225.
- [52] Hakomori S.I. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. *Cancer Res.* 1995; 45: 2405–2414.
- [53] Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung cancer adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. *Proteomics.* 2007; 7: 4292–4302.
- [54] Francina A., Roesch O.G., Couprie N., Leculier C., Col J.F., Archimbaud E., Campos L., Louisot P., Richard M. Glycosyltransferase activities in normal and leukaemic monocytic cells. *Clin Chim Acta.* 1989; 183: 301–308.
- [55] Helenius A., Aebi M. Intracellular functions of *N*-linked glycans. *Science.* 2001; 291: 2364–2369.

- [56] Ørntoft T.F., Vestergaard E.M. Clinical aspects of altered glycosylation of glycoproteins in cancer. *Electrophoresis*. 1999; 20: 362–371.
- [57] Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. *Nat Biotechnol*. 2006; 24: 1241–1250.
- [58] Tsim S., O’Dowd C.A, Milroy R., Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. *Respir Med*. 2010; 104: 1767–1774.
- [59] Tantipaiboonwong P., Sinchaikul S., Sriyam S., Phutrakul S., Chen S.T. Different techniques for urinary protein analysis of normal and lung cancer patients. *Proteomics*. 2005; 5: 1140–1149.
- [60] Lipman N.S., Jackson L.R., Trudel L.J., Garcia F.W. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. *ILAR J*. 2005; 258–268.
- [61] Kornfeld R., Kornfeld S. Assembly of asparagine-linked oligosaccharides. *Annu Rev Biochem*. 1995; 54: 631–664.
- [62] Glombitza G.J., Becker E., Kaiser H.W., Sandhoff K. Biosynthesis, processing, and intracellular transport of GM2 activator protein in human epidermal keratinocytes. The lysosomal targeting of the GM2 activator is independent of a mannose-6-phosphate signal. *J Biol Chem*. 1997; 272: 5199–5207.
- [63] Schepers U., Glombitza G., Lemm T., Hoffmann A., Chabas A., Ozand P., Sandhoff K. Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. *Am J Hum Genet*. 1996; 59: 1048–1056.
- [64] Peterson P.A. Characteristics of a vitamin A-transporting protein complex occurring in human serum. *J Biol Chem*. 1971; 246: 34–43.
- [65] Hakomori S. Glycosynapses: microdomains controlling carbohydrate-dependent cell adhesion and signaling. *An Acad Bras Cienc*. 2004; 76: 553–572.
- [66] Valentino L.A., Ladisch S. Localization of shed human tumor gangliosides: association with serum lipoproteins. *Cancer Res*. 1992; 52: 810–814.

- [67] Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. *Cancer Res.* 1996; 56: 5309–5318.
- [68] Molina H., Bunkenborg J., Reddy G.H., Muthusamy B., Scheel P.J., Pandey A. A proteomic analysis of human hemodialysis fluid. *Mol Cell Proteomics.* 2005; 4: 637–650.
- [69] Quiros Y., Ferreira L., Sancho-Martínez S.M., González-Buitrago J.M., López-Novoa J.M., López-Hernández F.J. Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. *Kidney Int.* 2010; 78: 1006–1015.
- [70] Haraldsson B., Sorensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. *News Physiol Sci.* 2004; 19: 7–10.
- [71] Chang D. Tumor markers research focus. New York: Nova Biomedical Books. 2007; 3–31: ISBN: 978-1-60021-544-5.
- [72] Check JH. CA-125 as a biomarker for malignant transformation of endometriosis. *Fertil Steril.* 2009; 91:e35; author reply e6.
- [73] Sok D., Clarizia L.J., Farris L.R., McDonald M.J. Novel fluoroimmunoassay for ovarian cancer biomarker CA-125. *Anal Bioanal Chem.* 2009; 393: 1521–1523.
- [74] Wei J., Gao W., Zhu C.J., Liu Y.Q., Mei Z., Cheng T., Shu Y.Q. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. *Chin J Cancer.* 2011; 30: 407–414.
- [75] Liu H., Zhu L., Liu B., Yang L., Meng X., Zhang W., Ma Y., Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. *Cancer Lett.* 2012; 316: 196–203.
- [76] Dutta S.K., Girotra M., Singla M., Dutta A., Otis S.F., Nair P.P., Merchant N.B. Serum HSP70: a novel biomarker for early detection of pancreatic cancer. *Pancreas.* 2012; 41: 530–534.

- [77] Khan S., Jutzy J.M., Valenzuela M.M., Turay D., Aspe J.R., Ashok A., Mirshahidi S., Mercola D., Lilly M.B., Wall N.R. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. *PLoS one*. 2012; 7: e46737.
- [78] Zhang F., Kaufman H.L., Deng Y., Drabier R. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. *BMC Med Genet*. 2013; 6 Suppl 1: S4.
- [79] Black P.H. Shedding from normal and cancer-cell surfaces. *N Engl J Med*. 1980; 303: 1415–1416.
- [80] Ladisch S., Gillard B., Wong C. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. *Cancer Res*. 1983; 43: 3808–3813.
- [81] Skipksi V.P., Katopodis N., Prendergast J.S., Stock C.C. Gangliosides in blood serum of normal rats and Morris hepatoma 5123tc-bearing rats. *Biochem Biophys Res Commun*. 1975; 67: 1122–1127.
- [82] Kloppel T.M., Keenan T.W., Freeman M.J., Morré D.J. Glycolipidbound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. *Proc Natl Acad Sci USA*. 1977; 74: 3011–3013.
- [83] Ladisch S., Wu Z.L. Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. *Lancet*. 1985; 1: 136–138.
- [84] Li R.X., Ladisch S. Shedding of human neuroblastoma gangliosides. *Biochim Biophys Acta*. 1991; 1083: 57–64.
- [85] Offner H., Thieme T., Vandenbark A.A. Gangliosides induce selective modulation of CD4 from helper T lymphocytes. *J Immunol*. 1987; 139: 3295–3305.
- [86] Chu J.W., Sharom F.J., Gangliosides interact with interleukin-4 and inhibit interleukin-4-stimulated helper T-cell proliferation. *Immunology*. 1995; 84: 396–403.
- [87] Grayson G., Ladisch S. Immunosuppression by human gangliosides II. Carbohydrate structure and inhibition of human NK activity. *Cell Immunol*. 1992; 139: 18–29.

- [88] Higashi K., Kubo H., Watanabe H., Fujimori K., Mikami T., Kaneko H. Adipokine ganglioside GM activator protein stimulates insulin secretion. *FEBS Letters*. 2011; 585: 2587–2591.
- [89] Rigata B., Yeger H., Shehnaz D., Mahuran D. GM2 activator protein inhibits platelet activating factor signaling in rats. *Biochem Biophys Res*. 2009; 385: 576–580.
- [90] Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. *Curr Opin Urol*. 2003; 13: 111–116.
- [91] International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International germ cell cancer collaborative group. *J Clin Oncol*. 1997; 15: 594–603.
- [92] Dennis J.W., Granovsky M., Warren C.E. Protein glycosylation in development and disease. *BioEssays*. 1999; 21: 412–421.
- [93] Meany D.L., Chan D.W. Aberrant glycosylation associated with enzymes as cancer biomarkers. *Clin Proteomics*. 2011; 8: 7.
- [94] Gu J., Taniguchi N. Potential of N-glycan in cell adhesion and migration as either a positive or negative regulator. *Cell Adh Migr*. 2008; 2: 243–245.
- [95] Kornfeld R., Kornfeld S. Assembly of asparagine-linked oligosaccharides. *Annu Rev Biochem*. 1995; 54: 631–664.
- [96] Stanca-Kaposta E.C., Liu B., Cocinero E.J., Vaden T.D., Frey J., Simons P., Snoek L.C. Towards the elucidation of 3D structure of rh N-linked glycoprotein: does rigidity play an important role?. *CLF Annual Report*. 2006-2007; 5: 143–146.
- [97] Matsumura K., Higashida K., Ishida H., Hata Y., Yamamoto K., Shigeta M., Mizuno-Horikawa Y., Wang X., Miyoshi E., Gu J., Taniguchi T. Carbohydrate-binding specificity of a fucose-specific lectin from *Aspergillus oryzae*: A novel probe for core fucose. *J Biol Chem*. 2007; 282: 15700–15708.

- [98] Fabini G., Freilinger A., Altmann F., Wilson I.B. Identification of core alpha 1,3-fucosylated glycans and cloning of the requisite fucosyltransferase cDNA from *Drosophila melanogaster*. Potential basis of the neural anti-horseadish peroxidase epitope. *J Biol Chem.* 2001; 276: 28058–28067.
- [99] Wendeler M., Lemm T., Weisgerber J., Hoernschemeyer J., Bartelsen O, Schepers U., Sandhoff K. Expression of recombinant human GM2-activator protein in insect cells: purification and characterization by mass spectrometry. *PREP.* 2003; 27: 259–266.
- [100] Varki A., Cummings R.D., Esko J.D., Freeze H.H., Stanley P., Bertozzi C.R., Hart G.W., Etzler M.E. *Essentials of Glycobiology*. Cold Spring Harbor (NY), 2nd edition. 2009, Chapter 41 Genetic disorders of glycan degradation, ISBN-13: 9780879697709.
- [101] Drake P.M., Cho W., Li B., Prakobphol A., Johansen E., Anderson N.L., Regnier F.E., Gibson B.W., Fisher S.J. Sweetening the pot: adding glycosylation to the biomarker discovery equation. *Clin Chem.* 2010; 56: 223–236.
- [102] Fukuda M. Possible roles of tumor-associated carbohydrate antigens. *Cancer Res.* 1996; 56: 2237–26244.